Ann: Nyrada Half Year Results FY2025, page-2

  1. 7,208 Posts.
    lightbulb Created with Sketch. 303
    nothing new IMHO
    Nyrada is in the early and crucial stages of development, where the risk is higher and the future potential depends on the success of their clinical trials.
    Loss - operating loss of AU$2.46 million, which is typical for early stage biotech
    first dosing expected before the end of March 2025

    nothing exciting
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
33.0¢
Change
-0.010(2.94%)
Mkt cap ! $69.60M
Open High Low Value Volume
34.0¢ 34.3¢ 32.5¢ $195.9K 589.3K

Buyers (Bids)

No. Vol. Price($)
2 14970 33.0¢
 

Sellers (Offers)

Price($) Vol. No.
33.5¢ 20100 1
View Market Depth
Last trade - 15.29pm 25/07/2025 (20 minute delay) ?
NYR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.